We read with great interest the prognostic model recently developed by Hahn et al 1 for predicting event-free survival (EFS) after stem cell transplantation (SCT) for relapsed and/ or refractory Hodgkin's disease (HD). However, we would like to comment further on the suggestion of potentially using such a model for selecting different and/or 'novel' allogeneic transplant approaches in this group of patients.
Over the last 14 years, we have performed a total of 12 allogeneic transplants for relapsed and/or refractory HD. Myeloablative conditioning was used in six cases (cyclophosphamide/TBI and busulphan/cyclophosphamide in three cases each), and nonmyeloablative preparative regimens in six (fludarabine/TBI in four, fludarabine/cyclophosphamide in one and fludarabine/melphalan in one). Donors included fully HLA-matched siblings in seven cases, single-HLA mismatched siblings in three and HLAmatched volunteer unrelated donors in two. Stem cell source used included G-CSF stimulated peripheral blood progenitor cells in eight cases and bone marrow in four. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine/methotrexate (days 1, 3, 6 711), or in the fludarabine/TBI conditioned patients, cyclosporine and mycophenolate mofetil.
In total, five patients died of transplant-related complications, including four of six patients conditioned myeloablative preparative regimens. Of the remaining seven patients, all suffered relapsed and/or progressive HD by 13 months post SCT. Significantly, at least moderate grade (X2) acute GVHD occurred in five patients prior to relapse and/or progression of their HD. At relapse, one patient received donor lymphocyte infusion without response, and one patient interferon 2b with minor response only, despite the induction of significant visceral GVHD. Overall, only four patients remain alive at median follow-up of 20 months (range 4-44 months) post transplantation. At 2 years, EFS (censored at death or relapse) is 0%.
Using the prognostic score developed by Hahn et al 1 six of our cohort had low-risk disease at SCT, and six poor risk (Table 1) . Although EFS was marginally superior in the low-risk group (median EFS 3.4 versus 2.0 months, respectively), this difference was not statistically significant (P ¼ 0.12; Figure 1 ). As such, we were unable to validate Hahn et al's. prognostic score for predicting EFS after allogeneic SCT for relapsed and/or refractory HD. Similar to other reports, our experience gives little supportive evidence for the occurrence of a significant graft-versus-lymphoma (GVL) effect post allogeneic SCT for advanced HD. 2, 3 While nonmyeloablative SCT may appear to be associated with significantly reduced transplant-related mortality in comparison to myeloablative approaches, given the multitude of nonmyeloablative preparative regimens and/or approaches now described, lack of long-term follow-up in published series, and controversy over the occurrence of a durable clinically significant GVL effect in HD, we believe that there is currently insufficient data to suggest non-myeloablative allogeneic SCT as a 'standard' therapy in this group of patients, irrespective of prognostic score. [1] [2] [3] [4] [5] [6] Indeed, we believe that the role of any allogeneic SCT in HD, including 
